by The global Natural Killer Cells Market is estimated to be valued at US$ 132.76 Mn in 2023 and is expected to exhibit a CAGR of 44.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Natural killer cells are cytotoxic lymphocytes that are involved in both innate and adaptive immune responses. They function to control and eliminate cancerous and virally infected cells. Natural killer cells therapy utilizes genetically modified natural killer cells to target and destroy cancer cells.
Market key trends:
One of the key trends in the natural killer cells market is the increasing adoption of NK cell therapy for cancer treatment. Several clinical trials evaluating the potential of natural killer cell therapy for cancer treatment are currently underway. For instance, a phase I clinical trial is evaluating the administration of allogeneic natural killer cells therapy in patients with relapsed or refractory acute myeloid leukemia. Positive results from ongoing clinical studies evaluating the safety and efficacy of NK cell therapy for different types of cancers are expected to drive the demand for natural killer cells over the forecast period.
SWOT Analysis
Strength: Natural killer cells have strong anti-tumor activity and can eliminate tumor cells without prior sensitization. They can also be used for manufacturing off-the-shelf cell therapies without the need to maintain an inventory of donor cells.
Weakness: Large scale production and storage of natural killer cells for clinical use is challenging. Their activity and phenotype can change during extensive culturing and passaging.
Opportunity: Growing prevalence of cancer worldwide is creating massive opportunity for natural killer cell therapies in clinical oncology. In addition, use of NK cells holds promise for the treatment of certain infectious diseases and immunotherapy.
Threats: High costs associated with production of natural killer cells at commercial scale through complex manufacturing processes. Stringent regulatory approvals for clinical use of NK cell therapies pose another threat.
Key Takeaways
The global Natural Killer Cells Market Growth is expected to witness high growth, exhibiting a CAGR of 44% over the forecast period, due to increasing demand for cell-based immunotherapies for cancer treatment.
North America is expected to dominate the global market owing to rising cancer incidence, favorable reimbursement policies, and presence of key market players in the region. Asia Pacific is poised to be the fastest growing market for natural killer cells driven by growing healthcare expenditure, increasing cancer research activities and presence of large patient pool.
Key players operating in the Natural Killer Cells market are GC Cell (GC Biopharma corp.), ImmunityBio, Inc., Nkarta, Inc., Takeda Pharmaceutical Company Limited, Sanofi S. A., Innate Pharma SA. These companies are focused on developing advanced NK cell therapies through new product launches, expansion of manufacturing facilities and clinical collaborations.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
